Related Experiment Videos
[Cardiology. I. Heart failure]
1Abteilung Innere Medizin III, Klinikum der Universität Heidelberg.
Insights
Heart failure treatment has evolved from increasing contractility to reducing afterload. Modern strategies prioritize life extension proven by randomized trials, unlike older methods focusing on symptoms.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Context:
- Heart failure management has shifted significantly over the past 30 years.
- Early treatments focused on increasing myocardial contractility.
- Current approaches emphasize afterload reduction and neurohormonal balance.
Purpose:
- To compare historical and contemporary medical treatments for heart failure.
- To highlight the evolution of pathophysiological understanding and therapeutic goals.
- To emphasize the necessity of randomized controlled trials for evaluating new heart failure therapies.
Summary:
- Treatment has evolved from general methods, diuretics, and digitalis to include afterload reduction (hydralazine/isosorbide dinitrate) and ACE inhibitors, demonstrating improved survival.
- Diuretics show no prognostic improvement, while digitalis offers symptomatic relief but not extended life.
- Management of ventricular tachyarrhythmias is complex; Class I antiarrhythmics are generally avoided, with betablockers or Class III agents considered cautiously. Implantable cardioverter-defibrillators are preferred for symptomatic patients.
Impact:
- This comparison underscores the paradigm shift in heart failure treatment, moving towards evidence-based strategies focused on survival.
- The findings emphasize the critical role of rigorous clinical trials in validating therapeutic advancements.
- The evolution in treatment reflects a deeper understanding of heart failure pathophysiology and its long-term management.
Abstract:
To compare the medical treatment of heart failure 30 years ago and at present implies more than the report of new therapeutic strategies and their application. First of all, there is a change in pathophysiological concepts: 30 years ago the therapeutic aim was the increase of myocardial contractility, currently afterload reduction without reactive activation of the sympatho-neuronal and of the renin-angiotensin system is aimed. In contrast to the situation 30 years ago, nowadays new therapeutic strategies can no longer be based on pathophysiological considerations or the demonstration of a potentially beneficial acute effect. The efficacy of any new treatment for heart failure has to be evaluated by controlled randomized trials with the primary end point of prolongation of life. The treatment of chronic heart failure 30 years ago was essentially based on general methods and on the application of diuretics and digitalis. Improved survival of patients with heart failure was first documented by afterload reduction with hydralazine/isosorbide dinitrate. Further improvement was achieved by application of ACE-inhibitors. For diuretics no results are available indicating improved prognosis. For digitalis two studies indicate symptomatic but no prognostic improvement. The treatment of heart failure with betablockers is not yet finally decided. Especially in the post-CAST area the drug treatment of ventricular tachyarrhythmias is very problematic. Class I antiarrhythmic drugs should generally be rather avoided. The application of betablockers or class III antiarrhythmic drugs maybe considered, although there is no proof. In symptomatic patients the implantation of a cardioverter/defibrillator system may be preferred.